Contura Vet is a global veterinary company based in Copenhagen, Denmark, focused on developing minimally invasive technologies that support long-term animal health and quality of life.
For more than 25 years, Contura has invested in research, manufacturing, and veterinary collaboration across equine and companion animal medicine.
Today, Contura Vet products are used internationally and supported by ongoing clinical studies, publication development, and veterinary education initiatives.
A minimally invasive injectable hydrogel developed for the treatment of Urethral Sphincter Mechanism Incompetence (USMI) in dogs — the leading cause of urinary incontinence in spayed female dogs.
Mictamid is injected into the urethral submucosa under cystoscopic guidance to support continence and improve quality of life.
A patented 2.5% injectable polyacrylamide hydrogel designed to support long-term joint health in horses and dogs.
Arthramid targets the synovial membrane to help restore joint homeostasis, support mobility, and improve comfort in cases of osteoarthritis and joint lameness.
Registered for equine use in New Zealand since 2020.
Contura Vet products are developed using the patented IL-X in-line cross-linking process designed to ensure structural consistency and biological compatibility across every batch.
Manufacturing and quality processes are maintained within GMP-certified facilities in Copenhagen, supporting the long-term reliability and clinical confidence expected by veterinary professionals internationally.
